Liu, Yongfeng http://orcid.org/0000-0002-8649-7892
Xu, Xianjin
Gao, Junyuan
Naffaa, Moawiah M.
Liang, Hongwu
Shi, Jingyi
Wang, Hong Zhan http://orcid.org/0000-0002-3371-2309
Yang, Nien-Du http://orcid.org/0000-0002-5261-7382
Hou, Panpan http://orcid.org/0000-0001-7694-2262
Zhao, Wenshan
White, Kelli McFarland
Kong, Wenjuan
Dou, Alex
Cui, Amy
Zhang, Guohui
Cohen, Ira S.
Zou, Xiaoqin
Cui, Jianmin http://orcid.org/0000-0002-9198-6332
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL126774)
Article History
Received: 2 January 2020
Accepted: 22 June 2020
First Online: 16 July 2020
Change Date: 21 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s42003-022-04375-9
Competing interests
: J.S. and J.C. are cofounders of a startup company VivoCor LLC, which is targeting I<sub>Ks</sub> for the treatment of cardiac arrhythmia. Other authors declare they have no competing interests.